Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/17/24
End: 06/16/28
Due: 06/16/29
Phase: N/A
Priority: Normal
Start: 06/30/25
End: 06/30/28
Due: 06/30/29
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations | NCT06378593 | 3H (Suzhou) Pharmaceuticals Co., Ltd. | user2@example.com | None | 2024-06-17 | 2028-06-16 | 2029-06-16 | - | - | 2025-07-14 |
| A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations | NCT06287918 | 3H (Suzhou) Pharmaceuticals Co., Ltd. | user2@example.com | None | 2025-06-30 | 2028-06-30 | 2029-06-30 | - | - | 2025-07-14 |